Abstracts tagged "clinical trial"

Abstract Number: 1123 • ACR Convergence 2025
Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates Long Term Efficacy and Safety in Patients with Uncontrolled Gout: Results from the 24-week Double-blind Extension of the Phase 3 DISSOLVE I Study
Alan Kivitz¹, Atul Singhal², Anand Patel³, Rehan Azeem⁴, Ben Peace⁵, Bhavisha Desai⁶ and Herbert Baraf⁷, ¹Altoona Center for Clinical Research, Duncansville, PA, ²SouthWest Arthritis Research Group, Mesquite, TX, ³Conquest Research, Winter Park, FL, USA, Winter Park, FL, ⁴Global MACD, Sobi Inc., Waltham, MA, ⁵Statistical Science, Sobi, Stockholm, Sweden, ⁶Sobi, Glastonbury, CT, ⁷The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC
Background/Purpose: Uncontrolled gout (UG) occurs when serum uric acid (sUA) levels remain persistently elevated despite use of oral urate-lowering therapies and can result in progressively…
Abstract Number: 0641 • ACR Convergence 2025
Safety and efficacy of autologous CD19-CAR T-cell therapy in patients with autoimmune disease – data from the CASTLE Phase I/II basket study
Melanie Hagen¹, Andreas Wirsching¹, Fabian Müller², Soraya Kharboutli³, Christina Bergmann¹, Sebastian Böltz¹, Jule Taubmann⁴, Carlo Tur¹, Laura Bucci¹, Simon Völkl³, Michael Aigner³, Sascha Kretschmann³, Louis Schuster⁴, Koray Tascilar⁴, Silvia Spoerl³, Ingrid Vasova³, Panagiotis Garantziotis¹, Daniel Aletaha⁵, Hans-Peter Kiener⁶, gerlando Natalello⁷, Franco Locatelli⁸, Maria Antonietta D'Agostino⁹, Aline Bozec¹, Linda Hanssens¹⁰, Dirk De Vries¹⁰, Ricardo Grieshaber-Bouyer¹¹, Andreas Mackensen¹² and Georg Schett¹³, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²University Hospital of Erlangen, Erlangen, Germany, ³Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵Medical University Vienna, Wien, Austria, ⁶Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁷Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁸IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁹Catholic University of the Sacred Heart, Rome, Rome, Italy, ¹⁰Miltenyi Biomedicine, Bergisch Gladbach, Bergisch Gladbach, Germany, ¹¹University Hospital Erlangen, Erlangen, Germany, ¹²Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ¹³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: Engineered T cells expressing a chimeric antigen receptor (CAR) binding CD19 are powerful tools to deplete B-cells, representing an attractive therapy for severe autoimmune…
Abstract Number: 0843 • ACR Convergence 2025
Efficacy and Safety of BMS-986353, a CD19-Directed Chimeric Antigen Receptor T Cell Therapy Manufactured Using a Next-Generation Process: Updated Data From a Phase 1 Trial in Patients With Systemic Sclerosis
Dinesh Khanna¹, David Korman², Elana Bernstein³, Neil Kramer⁴, Vikas Majithia⁵, Philip J. Mease⁶, Georg Schett⁷, Jacques Azzi⁸, Richard Nash⁹, Ran Reshef³, Mohammad Cherry¹⁰, Ernesto Ayala⁵, Matthew Schwede¹¹, Monalisa Ghosh¹², Fabian Müller¹³, Alisha Desai¹⁴, San-San Ou¹⁵, Sharmila Das¹⁴, Jerill Thorpe¹⁶, Melissa Harnois¹⁴, Alexis Melton¹⁶, Ashley Koegel¹⁶ and Margrit Wiesendanger⁸, ¹University of Michigan, Ann Arbor, MI, ²Mountain Rheumatology, Denver, CO, ³Columbia University Irving Medical Center, New York, NY, ⁴Overlook Medical Center; Atlantic Medical Group, Atlantic Health System, Summit, NJ, ⁵Mayo Clinic Hospital, Jacksonville, FL, ⁶Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸Icahn School of Medicine at Mount Sinai, New York, NY, ⁹Health One Cares, Denver, CO, ¹⁰Atlantic Health System, Morristown, NJ, ¹¹Swedish Cancer Institute, Seattle, WA, ¹²C. S. Mott Children's Hospital University of Michigan Health, Ann Arbor, MI, ¹³University Hospital of Erlangen, Erlangen, Germany, ¹⁴Bristol Myers Squibb, Princeton, NJ, ¹⁵Bristol Myers Squibb, Seattle, WA, ¹⁶Bristol Myers Squibb, Princeton
Background/Purpose: BMS-986353 (CC-97540) is an investigational CD19-directed T-cell therapy expressing the chimeric antigen receptor (CAR) used in globally-approved lisocabtagene maraleucel; it is manufactured via the…
Abstract Number: 0473 • ACR Convergence 2025
A Phase 2b Dose-Ranging Study of Peresolimab for Adults with RA
Jay Tuttle¹, Kirstin Griffing², Mark Genovese², Hyungmin Rha², So Young Park², Pia Yachi¹, Ajay Nirula¹, LANCE PFEIFER², Tami Jo Rayle², Jesus Abraham Simón-Campos³, Clifton Bingham⁴, Kevin Winthrop⁵, Daniel Aletaha⁶, Iain McInnes⁷, Yu Xue⁸, Yoshiya Tanaka⁹, Roy Fleischmann¹⁰, Paul Emery¹¹ and Michael Weinblatt¹², ¹Lilly Biotechnology Center, San Diego, CA, ²Eli Lilly and Company, Indianapolis, IN, ³Köhler & Milstein Research, UADY School of Medicine, Merida, Yucatan, Mexico, ⁴Johns Hopkins University, Baltimore, MD, ⁵Oregon Health & Science University, Portland, OR, ⁶Medical University Vienna, Wien, Austria, ⁷University of Glasgow, Glasgow, United Kingdom, ⁸Huashan Hospital, Fudan University, Shanghai, China (People's Republic), ⁹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ¹¹University of Leeds, Leeds, England, United Kingdom, ¹²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Peresolimab, a humanized IgG1 mAb, activates programmed cell death protein 1. In a phase 2a study, peresolimab demonstrated efficacy in participants (pts) with RA…
Abstract Number: 2694 • ACR Convergence 2025
Effect of Deucravacitinib Treatment on Renal Dysfunction–Associated Plasma Biomarkers From a Phase 2 Study in Patients With Systemic Lupus Erythematosus
Amit Saxena¹, Chun Wu², Brad Rovin³, Zahi Touma⁴, Xueer Chen⁵, Ilias Kouris⁶ and Jinqi Liu⁵, ¹Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ²Bristol Myers Squibb, Princeton, ³The Ohio State University, Columbus, OH, ⁴University of Toronto, Toronto, ON, Canada, ⁵Bristol Myers Squibb, Princeton, NJ, ⁶Bristol Myers Squibb, Boudry, Switzerland
Background/Purpose: Plasma biomarkers may play a role in understanding kidney health in patients with lupus, particularly in terms of early detection of lupus nephritis (LN),…
Abstract Number: 2454 • ACR Convergence 2025
Longitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-Derived CAR T-cell Therapy
Jonatan Tuncel¹, Trever Greene², Nicholas Brookhouser², Sandeep Kothapally Hanok¹, Seth Peng¹, Alison O’Conor¹, Parastoo Fazeli³, Jennifer Medlin⁴, Cara Bickers², Kelsea Hubka¹, Allison Aguilar¹, Wei Zhao¹, Kyla Omilusik¹, John Goulding¹, Tom Lee², Jode Goodridge², Marie Hu⁵, Veronika Bachanova⁵, Jeffrey Miller⁶, Matthew Lunning⁷, Rebecca Elstrom², Debra Zack¹, Vaneet Sandhu², Bahram Valamehr⁸ and Lilly Wong⁸, ¹Fate Therapeutics, San Diego, ²Fate Therapeutics, Inc., San Diego, ³UMN, ST PAUL, MN, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Minnesota, Minneapolis, ⁶University of Minnesota, Minneaspolis, MN, ⁷University of Nebraska Medical Center, Omaha, ⁸Fate Therapeutics, Inc., San Diego, CA
Background/Purpose: Autologous chimeric antigen receptor (CAR) T-cell therapy is an exciting new potential therapy for autoimmune diseases but limited in scope of application by logistical…
Abstract Number: 2333 • ACR Convergence 2025
Validation of a Corrected Axial Spondyoarthritis Metrology Index in 9 Randomized Clinical Trials
Dafne capelusnik¹, Philip Gardiner², Annelies Boonen³, Elena Nikiphorou⁴ and Sofia Ramiro⁵, ¹Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ²Altnagelvin Hospital, Londonderry, United Kingdom, ³Maastricht University Medical Centre+ & Maastricht University, Maastricht, Limburg, Netherlands, ⁴King’s College London, London, United Kingdom, ⁵Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The MOBILITY study showed that BASMI often misclassifies spinal mobility, especially in older and taller individuals. To address this, the Corrected AxSpA Metrology Index…
Abstract Number: 2020 • ACR Convergence 2025
Inebilizumab Efficacy and Safety in Patients with Common, Urgent, and Fibrotic Organ Manifestations of IgG4-RD: Subgroup Analyses from the MITIGATE Trial
Arezou Khosroshahi¹, Emma Culver², Wen Zhang³, Kazuichi Okazaki⁴, Yoshiya Tanaka⁵, Matthias Lohr⁶, nicolas schleinitz⁷, Xinxin Dong⁸, Sue Cheng⁸, Daniel Cimbora⁸ and John Stone⁹, ¹Emory University, Atlanta, GA, ²John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, ³Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁴Kansai Medical University Kori Hospital, Osaka, Japan, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Aix Marseille university, AP-HM, Marseille, France, ⁸Amgen, Thousand Oaks, CA, ⁹Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a progressive, systemic, fibroinflammatory disease characterized by unpredictable and recurring flares, leading to organ damage and decreased quality of life.…
Abstract Number: 1577 • ACR Convergence 2025
Intravenous cyclophosphamide in the treatment of progressive interstitial lung diseases associated with systemic sclerosis: a prospective randomized trial versus placebo (SCLEROCYC).
Luc Mouthon¹, David Launay², Sylvie leroy³, Christian AGARD⁴, Yannick Allanore⁵, Alice berezne¹, Emmanuel Bergot⁶, Boris Bienvenu⁷, Benjamin Chaigne¹, Pascal Cohen⁸, Bruno Crestani⁹, Anca Corondan¹⁰, bertrand Dunogue¹, Christian Lavigne¹¹, Jonathan London¹², Jean-Marc Naccache¹⁰, Gabriel Baron¹³, Alexis REGENT¹⁴, Benjamin Terrier¹⁵, Zahir AMOURA¹⁶, Charles Marquette¹⁰ and Philippe Ravaud¹³, ¹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ²Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U¹²⁸⁶ - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, ³AP HP, Paris, France, ⁴Internal medicine, Nantes University Hospital, Nantes, France, ⁵Université Paris Cité, Paris, France, ⁶CHU, Caen, France, ⁷Saint Joseph Hospital, Marseille, France, ⁸Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁹CHU, Paris, France, ¹⁰NA, Paris, France, ¹¹CHU, Angers, France, ¹²Hôpital Croix-Saint-Simon, Paris, France, ¹³Hôtel-Dieu, Université Paris Cité,, Paris, France, ¹⁴Hopital Cochin, Paris, France, ¹⁵Cochin Hospital, Paris, France, ¹⁶APHP, Paris, France
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Randomized controlled trials favoured the use of cyclophosphamide…
Abstract Number: 1449 • ACR Convergence 2025
Bimekizumab Demonstrated Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Lianne S. Gensler¹, Sofia Ramiro², Denis Poddubnyy³, Marina Magrey⁴, Irene E. van der Horst-Bruinsma⁵, Atul Deodhar⁶, Vanessa Taieb⁷, Diana Voiniciuc⁸, Natasha de Peyrecave⁹ and Martin Rudwaleit¹⁰, ¹Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²Leiden University Medical Center, Bunde, Netherlands, ³Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ⁴Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH, ⁵Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ⁶Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁷UCB, Colombes, France, ⁸UCB, Slough, United Kingdom, ⁹UCB, Brussels, Belgium, ¹⁰Bielefeld University, Medical School and University Medical Centre OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ has shown sustained efficacy to Week (Wk) 52…
Abstract Number: 1072 • ACR Convergence 2025
Inclusion of Older Adults in Pharmacologic Randomized Controlled Clinical Trials of Autoimmune Rheumatic Diseases: A Systematic Review
Manuel Carpio Tumba¹, Raisa Lomanto Silva², Lily Sung³, Laura C. Pedraza-Arévalo⁴, Sneha Gupta⁵, Jeenah Gwak⁶, Aida Mohamadi⁷, Diana Louden⁸, Rachael Stovall⁸, Namrata Singh⁹, Didem Saygin¹⁰, Sarah Lieber¹¹, Jiha Lee¹² and Sebastian E Sattui¹³, ¹University of Pittsburgh, Pittsburgh, PA, ²Massachusetts General Hospital, Boston, MA, ³Stanford University Hospital & Clinics, Hayward, CA, ⁴St. Barnabas Hospital, New York, NY, ⁵University of Pittsburgh Medical Center McKeesport, McKeesport, PA, ⁶Stanford University, Palo Alto, CA, ⁷Tehran University of Medical Sciences, Tehran, Iran, ⁸University of Washington, Seattle, WA, ⁹University of Washington, Bellevue, WA, ¹⁰Rush University Medical Center, Chicago, IL, ¹¹Hospital for Special Surgery, New York, NY, ¹²University of Michigan, Ann Arbor, MI, ¹³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: A growing number of older adults are living with autoimmune rheumatic diseases (AIRDs) as the global population is aging. And yet, they remain underrepresented…
Abstract Number: 0640 • ACR Convergence 2025
Impact of Clinically Important Improvements in Patient-Reported Outcomes on Disease Activity in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib or Placebo: Results From the Phase 2 SLEek Study
Vibeke Strand¹, Zahi Touma², Anca Askanase³, Christopher Saffore⁴, Denise Kruzikas⁵, Karim Masri⁵, Siran Fang⁵, Yi Peng⁶, Patti Katz⁷ and Marta Mosca⁸, ¹Stanford University School of Medicine, Palo Alto CA, Portola Valley, CA, ²University of Toronto, Toronto, ON, Canada, ³Columbia University Medical Center, New York, NY, ⁴AbbVie Inc., waukegan, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., Maple Grove, MN, ⁷UCSF, San Rafael, CA, ⁸University of Pisa, Pisa, Pisa, Italy
Background/Purpose: This analysis evaluated associations between clinically important improvements in patient-reported outcomes (PROs) and reduced disease activity from the phase 2 SLEek trial evaluating upadacitinib…
Abstract Number: 0816 • ACR Convergence 2025
Persistent Pain Despite Inflammatory Control in RA: A Pooled Analysis of 7 RCTs
Andreas Kerschbaumer¹, Marlene Steiner², William H. Robinson³, Josef Smolen⁴ and Daniel Aletaha⁵, ¹Stanford University / Medical University of Vienna, Stanford, CA, ²Medical University of Vienna, Vienna, Wien, Austria, ³Stanford University, Palo Alto, CA, ⁴Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁵Medical University Vienna, Wien, Austria
Background/Purpose: Joint swelling and tenderness are clinical hallmarks of rheumatoid arthritis (RA) and central to disease assessment. Regardless of treatment type, stringent remission based on…
Abstract Number: 0470 • ACR Convergence 2025
Characterization of Patients With Rheumatoid Arthritis Based on Distinct Patterns of Pain Improvement Following Treatment With Filgotinib: A Post Hoc Analysis of FINCH 1
Peter Taylor¹, Yoshiya Tanaka², Louis Dron³, Katrien Van Beneden⁴, Gerd Burmester⁵ and Bruno Fautrel⁶, ¹University of Oxford, Oxford, United Kingdom, ²University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Cytel, Toronto, Canada, ⁴Alfasigma S.p.A., Bologna, Italy, ⁵Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁶Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: Janus kinase inhibitors have been shown to ameliorate pain as well as inflammation in patients with rheumatoid arthritis (RA). Pain response trajectories were modeled…
Abstract Number: 2692 • ACR Convergence 2025
Individualized Strength, Mobility and Aerobic Rehabilitation Training in axial Spondyloarthritis (iSMART in axSpA)
Sophie De Mits¹, Tine Willems², Lieven Danneels², Patrick Calders², Gaëlle Varkas³, Filip Van den Bosch⁴, Dirk Elewaut⁵ and Philippe Carron⁶, ¹Ghent University Hospital, Gent, Belgium, ²Ghent University, Gent, Belgium, ³Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁴Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ⁶Ghent University and VIB Center for Inflammation Research, Ghent, Belgium
Background/Purpose: AxSpA primarily affects the sacroiliac joints and spine, reducing trunk strength, mobility, and cardiorespiratory fitness. While exercise is a key treatment, few studies have…

« Previous Page
1
…
8
9
10
11
12
…
55
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].